JP2015535270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535270A5 JP2015535270A5 JP2015540120A JP2015540120A JP2015535270A5 JP 2015535270 A5 JP2015535270 A5 JP 2015535270A5 JP 2015540120 A JP2015540120 A JP 2015540120A JP 2015540120 A JP2015540120 A JP 2015540120A JP 2015535270 A5 JP2015535270 A5 JP 2015535270A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- diseases
- agent
- convulsions
- allergy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000018569 Respiratory Tract disease Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000029162 bladder disease Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000026533 urinary bladder disease Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12190859.4 | 2012-10-31 | ||
| EP12190859 | 2012-10-31 | ||
| PCT/EP2013/072774 WO2014068035A1 (en) | 2012-10-31 | 2013-10-31 | Novel rock inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015535270A JP2015535270A (ja) | 2015-12-10 |
| JP2015535270A5 true JP2015535270A5 (enExample) | 2016-12-22 |
| JP6205425B2 JP6205425B2 (ja) | 2017-09-27 |
Family
ID=47148627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540120A Expired - Fee Related JP6205425B2 (ja) | 2012-10-31 | 2013-10-31 | 新規のｒｏｃｋ阻害剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9394286B2 (enExample) |
| EP (1) | EP2914590B1 (enExample) |
| JP (1) | JP6205425B2 (enExample) |
| KR (1) | KR102242280B1 (enExample) |
| CN (1) | CN104822676B (enExample) |
| AU (1) | AU2013340854B2 (enExample) |
| BR (1) | BR112015009504A2 (enExample) |
| CA (1) | CA2922312C (enExample) |
| DK (1) | DK2914590T3 (enExample) |
| EA (1) | EA026629B1 (enExample) |
| ES (1) | ES2617495T3 (enExample) |
| IL (1) | IL238391A (enExample) |
| IN (1) | IN2015DN04311A (enExample) |
| MX (1) | MX362485B (enExample) |
| NZ (1) | NZ708526A (enExample) |
| PL (1) | PL2914590T3 (enExample) |
| PT (1) | PT2914590T (enExample) |
| SG (1) | SG11201503134WA (enExample) |
| WO (1) | WO2014068035A1 (enExample) |
| ZA (1) | ZA201503544B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| US11202773B2 (en) * | 2015-04-20 | 2021-12-21 | University Of Houston System | Locally bioavailable drugs |
| CN106928252B (zh) * | 2015-12-31 | 2019-09-27 | 成都先导药物开发股份有限公司 | 一种抑制rock的化合物及其制备方法与应用 |
| EP3693380A1 (en) * | 2019-02-11 | 2020-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Dual inhibition of plexin-b1 and plexin-b2 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| AU2022385051A1 (en) | 2021-11-11 | 2024-06-20 | Actualeyes Inc. | Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
| US20090325959A1 (en) | 2008-06-26 | 2009-12-31 | Vittitow Jason L | Method for treating ophthalmic diseases using rho kinase inhibitor compounds |
| US20090325960A1 (en) | 2008-06-26 | 2009-12-31 | Fulcher Emilee H | Method for treating inflammatory diseases using rho kinase inhibitor compounds |
| US8299096B2 (en) | 2008-06-26 | 2012-10-30 | Inspire Pharmaceuticals, Inc. | Method for treating pulmonary diseases using rho kinase inhibitor compounds |
| EP2400969A4 (en) | 2008-12-04 | 2012-05-16 | Inspire Pharmaceuticals Inc | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITORY COMPOUNDS |
| CA2781390A1 (en) | 2009-12-14 | 2011-06-23 | Inspire Pharmaceuticals, Inc. | Bridged bicyclic rho kinase inhibitor compounds, composition and use |
| RU2013107007A (ru) * | 2010-07-19 | 2014-08-27 | Инспайр Фармасьютикалз, Инк. | Бифункциональные соединения, являющиеся ингибиторами rho-киназы, композиция и применение |
| WO2012015760A1 (en) * | 2010-07-27 | 2012-02-02 | Inspire Pharmaceuticals, Inc. | Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms |
| GB201107223D0 (en) * | 2011-04-29 | 2011-06-15 | Amakem Nv | Novel rock inhibitors |
-
2013
- 2013-10-31 PT PT137864559T patent/PT2914590T/pt unknown
- 2013-10-31 WO PCT/EP2013/072774 patent/WO2014068035A1/en not_active Ceased
- 2013-10-31 US US14/437,919 patent/US9394286B2/en not_active Expired - Fee Related
- 2013-10-31 EP EP13786455.9A patent/EP2914590B1/en active Active
- 2013-10-31 PL PL13786455T patent/PL2914590T3/pl unknown
- 2013-10-31 JP JP2015540120A patent/JP6205425B2/ja not_active Expired - Fee Related
- 2013-10-31 MX MX2015005459A patent/MX362485B/es active IP Right Grant
- 2013-10-31 BR BR112015009504A patent/BR112015009504A2/pt not_active Application Discontinuation
- 2013-10-31 KR KR1020157014431A patent/KR102242280B1/ko not_active Expired - Fee Related
- 2013-10-31 EA EA201590847A patent/EA026629B1/ru unknown
- 2013-10-31 IN IN4311DEN2015 patent/IN2015DN04311A/en unknown
- 2013-10-31 NZ NZ708526A patent/NZ708526A/en not_active IP Right Cessation
- 2013-10-31 CN CN201380056608.XA patent/CN104822676B/zh not_active Expired - Fee Related
- 2013-10-31 CA CA2922312A patent/CA2922312C/en active Active
- 2013-10-31 AU AU2013340854A patent/AU2013340854B2/en not_active Ceased
- 2013-10-31 ES ES13786455.9T patent/ES2617495T3/es active Active
- 2013-10-31 DK DK13786455.9T patent/DK2914590T3/en active
- 2013-10-31 SG SG11201503134WA patent/SG11201503134WA/en unknown
-
2015
- 2015-04-20 IL IL238391A patent/IL238391A/en active IP Right Grant
- 2015-05-20 ZA ZA2015/03544A patent/ZA201503544B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535270A5 (enExample) | ||
| EA201591269A1 (ru) | Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта | |
| MX2018002631A (es) | Inhibidores de molecula pequeña de dyrkia y usos de los mismos. | |
| SG11201911929XA (en) | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | |
| EP3718561A4 (en) | Therapy for inflammatory bowel disease | |
| CL2019000129A1 (es) | Compuestos diazaheterobicíclicos sustituidos y su uso. | |
| PL3405215T3 (pl) | Sposoby leczenia choroby danona i innych zaburzeń autofagii | |
| NZ741082A (en) | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses | |
| IL273169A (en) | A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases | |
| WO2009043522A3 (en) | Use of a peptide as a therapeutic agent | |
| EA201891374A1 (ru) | Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение | |
| EA201992607A1 (ru) | Твердые формы берберина урсодезоксихолата, их композиции и способы | |
| WO2010151640A3 (en) | Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease | |
| IL283469A (en) | Inhalable preparations for use in the treatment of lung diseases | |
| JP2016512817A5 (enExample) | ||
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| HRP20191240T1 (hr) | Terapija matičnim stanicama kod patologija endometrija | |
| MA39950A (fr) | Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie | |
| EP3402527A4 (en) | THERAPEUTIC NANOPARTICLES FOR THE TREATMENT OF NEUROBLASTOM AND OTHER CANCER TYPES | |
| MY173990A (en) | Bicyclic compounds | |
| JP2013523758A5 (enExample) | ||
| EP3664850A4 (en) | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY INTESTINAL DISEASES | |
| JP2016523943A5 (enExample) |